Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Conflicts can be great for business — when they’re someone else’s, of course. Cooley Godward picked up a new client when Latham & Watkins found itself representing both acquirer ArthroCare Corp. and its target, Opus Medical Inc., in what would become a $130 million deal. Latham & Watkins’ Northern California offices had worked with Sunnyvale-based ArthroCare, while its Orange County outpost counseled Opus, based in San Juan Capistrano. So Latham & Watkins tapped Palo Alto-based Cooley Godward to counsel Opus. Charles Ruck, an Orange County-based Latham partner, introduced Cooley and Opus. Ruck had worked previously with Cooley’s Suzanne Sawochka Hooper, who became the lead partner in the transaction for Cooley. No sooner did Cooley lawyers meet their new client than the deal kicked off. “We got to know them very quickly,” said Cooley associate Kathryn Walker Hall, who worked on the deal. ArthroCare Corp., a medical device company that develops minimally invasive tools for arthroscopic and other surgeries, will absorb Opus, a maker of soft-tissue orthopedic repair systems. ArthroCare will acquire all of the capital stock of Opus Medical for $90 million in cash and stock and $40 million of ArthroCare’s Nasdaq-traded stock payable in January 2006, according to Hall. In addition, former Opus shareholders may receive earn-out payments in 2006 if certain sales milestones are met in 2005. Hall said the earn-out agreements made the deal interesting. “Whenever you work with contingency payments, it raises a host of issues and makes it more complicated,” she said. The deal, which was announced earlier this week, is expected to close before the end of 2004. At that point, Opus will once again be a client of Latham’s — this time as part of ArthroCare. Along with Hooper and Hall, Cooley Godward’s team included partners William Morrow and Judith Hasko and associates Cara Franklin, Karla Galvez and Shane Albright. John Newell led Latham & Watkin’s team, which included Menlo Park-based associate Linda Lorenat.Adrienne Sanders EASY COME, EASY GO It looked good on paper. But nine months after Charles Schwab & Co. plunked down about $324 million for a securities research firm, the company had second thoughts about the purchase. Last week, the San Francisco-based brokerage firm announced that it was selling the business to UBS AG for $265 million in cash. The lawyers at Howard, Rice, Nemerovski, Canady, Falk & Rabkin who helped Schwab buy SoundView Technology Group Inc. were brought in to sell the business off. Partner Richard Canady, who led the team, declined to comment on the deal. Schwab purchased SoundView, an Old Greenwich, Conn.-based firm that provides institutional investors with research on technology, telecom and health care companies, in December. At the time Schwab said it expected the business, renamed Schwab SoundView Capital Markets, would provide an alternative to traditional Wall Street research and trading businesses. But in an Aug. 31 release, Schwab Chairman and CEO Charles Schwab said he had concluded there was “not enough synergy” between SoundView and Schwab’s core businesses to justify the company’s continued investment in the capital markets arena. “Our exit from capital markets reinforces our strategic focus on individual investors and independent financial advisers,” Schwab said. The Howard, Rice team included partners Stuart Lipton, Joseph Hershenson, Jennifer Blackman and J. Alex Moore and associates Edward Deibert, Tracey Luttrell, Maurine Murtagh, Celia van Gorder and Stephen Fronk. Schwab’s vice president and chief of staff Susan Stapleton and in-house counsel Mark Tellini also worked on the deal. Sullivan & Cromwell represented UBS on the transaction. The team included Palo Alto partner Matthew Hurd and New York partners Alexandra Korry, Frederick Wertheim, Ronald Creamer Jr. and Marc Trevino, as well as associates Scott Sonnenblick, Avner Ben-Gera, Nia Brown, Jennifer Palm, Sandra Cohen, David Passey and Joseph Ferraro. – Brenda Sandburg

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]

Reprints & Licensing
Mentioned in a Law.com story?

License our industry-leading legal content to extend your thought leadership and build your brand.


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.